PURPOSE: We present a series of @entity6369 following a pubovaginal sling procedure due to synthetic and nonsynthetic materials and discuss their management and continence outcome. MATERIALS AND METHODS: During a 3-year period 57 @entity1 underwent urethrolysis for @entity11044 after receiving a pubovaginal sling. @entity6369 , defined as sling material entering the urethral lumen, was present in 9 @entity1 and this cohort comprises the focus of our review. In 3 @entity1 the eroded material was synthetic, that is ProteGen (Boston Scientific, Natick, Massachusetts) in 2 and @entity7502 in 1. This condition was treated with removal of the whole sling, multilayer closure of the erosion and selective use of a Martius flap. In 6 @entity1 the eroded material was nonsynthetic, that is allograft fascia in 5 and autograft fascia in 1. This condition was treated with sling incision and multilayer closure of the urethra. Preoperative assessment included a urogynecologic questionnaire, measurement of pad use, a voiding diary, cystourethroscopy and videourodynamics. Postoperatively similar parameters were used to assess continence outcomes and the need for subsequent procedures. RESULTS: Nine @entity1 were followed 30 months after urethrolysis. All 9 @entity1 had some manifestation of @entity409 following the pubovaginal sling procedure, including urinary retention in 4, urge @entity322 in 3 and mixed @entity322 in 2. Urinary retention resolved in 3 @entity1 and urge @entity322 resolved in 4. @entity3142 ( @entity3142 ) persisted in 2 of the 3 @entity1 in the synthetic group, while no @entity1 in the nonsynthetic group had recurrent @entity3142 . There were no recurrent @entity6369 or @entity292 in either group. CONCLUSIONS: @entity6369 after a pubovaginal sling procedure can occur irrespective of the sling material. However, recurrent @entity3142 is not an invariable outcome of the management of @entity6369 following the pubovaginal sling procedure.

XXXX after synthetic and nonsynthetic pubovaginal slings: differences in management and continence outcome.

@entity6369 :: ('MESH:D014526', 'Disease') :: ['urethral erosion', 'urethral erosions', 'Urethral erosion'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient'] @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence'] @entity7502 :: ('MESH:D011126', 'Chemical') :: ['polypropylene'] @entity409 :: ('MESH:D008107', 'Disease') :: ['voiding dysfunction'] @entity292 :: ('MESH:D005402', 'Disease') :: ['fistulas'] @entity3142 :: ('MESH:D014550', 'Disease') :: ['Stress urinary incontinence', 'SUI'] @entity11044 :: ('MESH:D014524', 'Disease') :: ['urethral obstruction']
@entity6369 :: (MESH:D014526,Disease) :: ['Urethral erosion']
